Who We Are

Steve Potts, PhD, MBA has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He was founding CEO of OncoMyx Therapeutics, raising $75M of venture capital for an oncolytic virus tumor program. Previously, he was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule (www.rozlytrek.com) was the first in industry to receive breakthrough designation equivalents in USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M, and helped create the widespread adoption by pharma of the digital pathology technology that has enabled pathology artificial intelligence. He also built the original Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, now handling over $2B of annual revenue, and the largest diagnostics lab network in the United States. He holds a Ph.D. in Bioengineering and an MBA from the University of California at Davis, and a B.S. in Physics from Wheaton College, Illinois. 

Steve Potts, PhD, MBA has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He was founding CEO of OncoMyx Therapeutics, raising $75M of venture capital for an oncolytic virus tumor program. Previously, he was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule (www.rozlytrek.com) was the first in industry to receive breakthrough designation equivalents in USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M, and helped create the widespread adoption by pharma of the digital pathology technology that has enabled pathology artificial intelligence. He also built the original Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, now handling over $2B of annual revenue, and the largest diagnostics lab network in the United States. He holds a Ph.D. in Bioengineering and an MBA from the University of California at Davis, and a B.S. in Physics from Wheaton College, Illinois.